TYSABRI® Global Observational Program in Safety (TYGRIS)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Elan Pharmaceuticals
Information provided by:
Biogen Idec
ClinicalTrials.gov Identifier:
NCT00477113
First received: May 21, 2007
Last updated: August 2, 2012
Last verified: August 2012

May 21, 2007
August 2, 2012
January 2007
September 2014   (final data collection date for primary outcome measure)
To determine the incidence and pattern of serious infections, malignancies, and other serious adverse events (SAEs) in patients with Multiple Sclerosis (MS) treated with Tysabri. [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
Not Provided
Complete list of historical versions of study NCT00477113 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
TYSABRI® Global Observational Program in Safety
TYGRIS: TYSABRI® Global Observational Program in Safety

The purpose of this study is to determine the incidence and pattern of serious infections, malignancies, and other serious adverse events in patients with multiple sclerosis (MS) treated with TYSABRI® (natalizumab).

The TYSABRI® Global Observational Program in Safety (TYGRIS) is a safety observational cohort program designed to obtain long-term safety data in multiple sclerosis (MS) patients treated with TYSABRI® in a clinical practice setting in the United States or Canada.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

whole blood, serum

Non-Probability Sample

MS patients treated with TYSABRI in North America

Multiple Sclerosis
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
3000
September 2014
September 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • MS patients in the US and Canada receiving TYSABRI® under standard clinical care for less than or equal to 3 infusions are eligible to participate in TYGRIS.
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00477113
101-MS-402
No
Biogen Idec MD, Biogen Idec, Inc.
Biogen Idec
Elan Pharmaceuticals
Not Provided
Biogen Idec
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP